CN102300876A - 针对组织因子途径抑制剂(tfpi)的抗体 - Google Patents

针对组织因子途径抑制剂(tfpi)的抗体 Download PDF

Info

Publication number
CN102300876A
CN102300876A CN2009801555207A CN200980155520A CN102300876A CN 102300876 A CN102300876 A CN 102300876A CN 2009801555207 A CN2009801555207 A CN 2009801555207A CN 200980155520 A CN200980155520 A CN 200980155520A CN 102300876 A CN102300876 A CN 102300876A
Authority
CN
China
Prior art keywords
antibody
tfpi
amino acid
seq
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN2009801555207A
Other languages
English (en)
Chinese (zh)
Inventor
I.希尔登
J.T.克劳森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN102300876A publication Critical patent/CN102300876A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801555207A 2008-12-22 2009-12-18 针对组织因子途径抑制剂(tfpi)的抗体 Withdrawn CN102300876A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172522 2008-12-22
EP08172522.8 2008-12-22
PCT/EP2009/067566 WO2010072687A1 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
CN102300876A true CN102300876A (zh) 2011-12-28

Family

ID=42104649

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801555207A Withdrawn CN102300876A (zh) 2008-12-22 2009-12-18 针对组织因子途径抑制剂(tfpi)的抗体

Country Status (6)

Country Link
US (2) US8618263B2 (https=)
EP (1) EP2379599B1 (https=)
JP (1) JP5791512B2 (https=)
CN (1) CN102300876A (https=)
TW (1) TW201026329A (https=)
WO (1) WO2010072687A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687482A (zh) * 2014-09-17 2017-05-17 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1‑161)上的两个表位的抗体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
BR112021006223A2 (pt) 2018-10-11 2021-07-06 Pfizer regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
WO2025124481A1 (zh) * 2023-12-13 2025-06-19 苏州康宁杰瑞生物科技有限公司 Tfpi抗体用于治疗血友病

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARSTEN WINKLER，ET AL.: "Changing the Antigen Binding Specificity by Single Point", 《JOURNAL OF IMMUNOLOGY》 *
杨寅柯等: "抗组织因子途径抑制物单克隆抗体的制备及鉴定", 《中华血液学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687482A (zh) * 2014-09-17 2017-05-17 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1‑161)上的两个表位的抗体

Also Published As

Publication number Publication date
US20110268745A1 (en) 2011-11-03
JP2012513193A (ja) 2012-06-14
EP2379599A1 (en) 2011-10-26
US20130344090A1 (en) 2013-12-26
TW201026329A (en) 2010-07-16
WO2010072687A1 (en) 2010-07-01
JP5791512B2 (ja) 2015-10-07
US8618263B2 (en) 2013-12-31
EP2379599B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
CN102300876A (zh) 针对组织因子途径抑制剂(tfpi)的抗体
CN105944100B (zh) 针对组织因子途径抑制剂(tfpi)的单克隆抗体
KR102035882B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
CN105001335B (zh) 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
US12186379B2 (en) Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
CN103687620A (zh) 用于抑制masp-2依赖的补体活化的组合物
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
RS65630B1 (sr) Farmaceutska kompozicija za upotrebu u lečenju ili prevenciji bolesti povezane sa c5
JP2015531350A (ja) 末端修飾を有する抗原結合分子
KR20180096567A (ko) Xiia 인자의 단일클론 항체 저해제
BR112019015479A2 (pt) Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
US20150210775A1 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN100457901C (zh) 人抗人白介素-18抗体及其片断和它们的利用方法
US12460010B2 (en) Antibodies that bind TNFRSF25
JP7127859B2 (ja) キメラタンパク質を用いたアレルギー疾患の治療
EP4230652A1 (en) Anti-oscar antibody for preventing or treating osteoarthritis
CN112585273A (zh) 诱导免疫耐受的抗体、所诱导的淋巴细胞、以及使用所诱导的淋巴细胞的细胞治疗剂治疗法
WO2023125485A9 (en) TrkB ANTIBODY AND APPLICATION THEREOF
RU2816592C2 (ru) Антитела, индуцирующие иммунную толерантность, индуцированные лимфоциты и терапевтический агент/способ клеточной терапии с использованием индуцированных лимфоцитов
RU2820628C2 (ru) Белки, связывающие глюкагоновые рецепторы, и способы их применения
HK40096491A (zh) 一种因子xiia的单克隆抗体抑制剂
WO2024214026A2 (en) Steap2 directed t-cell engagers and compositions thereof
CN119233992A (zh) 抗活化蛋白c的人抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20111228